Figure 3.
Cumulative incidence of NRM depending on CMV reactivation, in vivo T cell depletion and disease stage. Cumulative incidence function of nonrelapse mortality (NRM) with relapse as competing risk (60 months censored). Patients with CMV reactivation (blue) and without CMV reactivation (red). Median (line) with 95% CI shaded. (A) AML advanced disease stages without ATG (n = 256). (B) AML advanced disease stages with ATG (n = 138). (C) AML in CR1 without ATG (n = 164). (D) AML in CR1 with ATG (n = 129). All P values refer to comparisons of strata with Gray’s test.

Cumulative incidence of NRM depending on CMV reactivation, in vivo T cell depletion and disease stage. Cumulative incidence function of nonrelapse mortality (NRM) with relapse as competing risk (60 months censored). Patients with CMV reactivation (blue) and without CMV reactivation (red). Median (line) with 95% CI shaded. (A) AML advanced disease stages without ATG (n = 256). (B) AML advanced disease stages with ATG (n = 138). (C) AML in CR1 without ATG (n = 164). (D) AML in CR1 with ATG (n = 129). All P values refer to comparisons of strata with Gray’s test.

Close Modal

or Create an Account

Close Modal
Close Modal